Archived: Re-purposing Existing Drugs to Treat COVID-19 | Process Chemistry Issues
Date: 15 June 2020
The battle against Covod-19 is being fought on a number of fronts, including the use of small molecule antiviral drugs. Long development times and extensive safety testing mean that de novo design and development of a bespoke molecule could be many years away. The need for rapid pharmacological intervention has triggered a world-wide search for existing drugs that could be repurposed for emergency use in the current pandemic. The synthesis of the compounds can challenging, particularly at scale, and especially if the intended purpose was to treat thousands rather than millions of people.
This webinar looked at the synthesis of drugs that are being trialled as a treatment for Covid-19 and how the synthetic routes have evolved during the development lifecycle of the molecules. The content will be of interest to discovery and process chemists, synthetic organic chemists and anyone interested in the pharmaceutical industries armoury of antiviral chemotherapeutics.
This webinar was presented by Dr John Studley, Scientific Update.